The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti–PD-1 treatment
Open accessAbstract
Significance: Cancer immunotherapy is a promising therapeutic intervention. However, complete and durable responses are seen in only a fraction of cancer patients. A key factor that limits therapeutic success is the lack of T cells in tumor cell regions, a profile termed “immune-excluded.” Here, we provide evidence that tumor-associated macrophages (TAMs) are an important determinant of the establishment of a T cell-excluded tumor phenotype. In human and murine tumors, we found that CD8 T cells poorly migrate and invade tumor nests due to long-lasting interactions with TAMs. The depletion of TAMs restores T cell migration and infiltration into tumor islets and improves the efficacy of anti–PD-1 immunotherapy. This study highlights the rationale of combining approaches targeting TAM and immune checkpoint proteins.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Elements of cancer immunity and the cancer–immune set point
Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352 · cited 3×
“Approaches that target cells such as TAMs or factors including TGFβ, responsible for the formation of a mesenchymal stroma and for immunosuppression, are promising (2).”
BackgroundPredictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231 · cited 4×
“Discussion Growing evidence supports the notion that clinical response to anti–PD-1 immunotherapies is associated with the presence of CD8+ T cells in tumor cell regions before the treatment (5).”
BackgroundResultInfluentialMacrophage biology in development, homeostasis and disease
Wynn, T. A., Chawla, A., & Pollard, J. W. (2013) · Nature · doi:10.1038/nature12034 · Cited by 4,684 · cited 1×
“Of note, M2like CD206 macrophages are known to play important roles in promoting each of these processes (45).”
BackgroundTumour-associated macrophages as treatment targets in oncology
Mantovani, A., Marchesi, F., Malesci, A., Laghi, L., & Allavena, P. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.217 · Cited by 4,033
Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm
Biswas, S. K., & Mantovani, A. (2010) · Nature Immunology · doi:10.1038/ni.1937 · Cited by 3,840
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Hugo, W., Zaretsky, J. M., Sun, L., Song, C., Moreno, B. H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.065 · Cited by 3,448
T cell exclusion, immune privilege, and the tumor microenvironment
Joyce, J. A., & Fearon, D. T. (2015) · Science · doi:10.1126/science.aaa6204 · Cited by 2,473
Feig, C., Jones, J. O., Kraman, M., Wells, R. J. B., Deonarine, A., Chan, D. S., Connell, C. M., Roberts, E. W., Zhao, Q., Caballero, O. L., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1320318110 · Cited by 2,100 · cited 1×
“In pancreatic tumors, CXCL12 produced by carcinomaassociated fibroblasts has been shown to be another element sequestering CD8 T cells in the tumor stroma, away from tumor cells (12).”
BackgroundDeNardo, D. G., Brennan, D. J., Rexhepaj, E., Ruffell, B., Shiao, S. L., Madden, S. F., Gallagher, W. M., Wadhwani, N., Keil, S. D., Junaid, S. A., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8274.cd-10-0028 · Cited by 1,715
Macrophages and Therapeutic Resistance in Cancer
Ruffell, B., & Coussens, L. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.02.015 · Cited by 1,474 · cited 2×
“Many mechanisms have been proposed, such as a block of T cell proliferation or their cytotoxic activities (18, 19).”
BackgroundSpranger, S., Dai, D., Horton, B., & Gajewski, T. F. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.04.003 · Cited by 1,441
Zhu, Y., Knolhoff, B. L., Meyer, M. A., Nywening, T. M., West, B. L., Luo, J., Wang-Gillam, A., Goedegebuure, S. P., Linehan, D. C., & DeNardo, D. G. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3723 · Cited by 1,324
Broz, M. L., Binnewies, M., Boldajipour, B., Nelson, A. E., Pollack, J. L., Erle, D. J., Barczak, A., Rosenblum, M. D., Daud, A., Barber, D. L., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.09.007 · Cited by 1,207
Salmon, H., Franciszkiewicz, K., Damotte, D., Dieu-Nosjean, M.-C., Validire, P., Trautmann, A., Mami-Chouaib, F., & Donnadieu, E. (2012) · Journal of Clinical Investigation · doi:10.1172/jci45817 · Cited by 1,138
Self-citationStromal gene expression defines poor-prognosis subtypes in colorectal cancer
Calon, A., Lonardo, E., Berenguer-Llergo, A., Espinet, E., Hernando-Momblona, X., Iglesias, M., Sevillano, M., Palomo-Ponce, S., Tauriello, D. V. F., Byrom, D., et al. (2015) · Nature Genetics · doi:10.1038/ng.3225 · Cited by 1,070
Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy
Cannarile, M. A., Weisser, M., Jacob, W., Jegg, A.-M., Ries, C. H., & Rüttinger, D. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0257-y · Cited by 1,020
Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR–induced stop signal
Fife, B. T., Pauken, K. E., Eagar, T. N., Obu, T., Wu, J., Tang, Q., Azuma, M., Krummel, M. F., & Bluestone, J. A. (2009) · Nature Immunology · doi:10.1038/ni.1790 · Cited by 759
Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies
Anderson, K. G., Stromnes, I. M., & Greenberg, P. D. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.02.008 · Cited by 702
Arlauckas, S. P., Garris, C. S., Kohler, R. H., Kitaoka, M., Cuccarese, M. F., Yang, K. S., Miller, M. A., Carlson, J. C., Freeman, G. J., Anthony, R. M., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal3604 · Cited by 669 · cited 1×
“Unrelated to the latter mechanisms, it has recently been suggested that TAMs promoted resistance to anti–PD-1 strategy through another mechanism dependent on Fc receptors and the removal of the monoclonal antibody from T cells (48).”
BackgroundSaha, D., Martuza, R. L., & Rabkin, S. D. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.07.006 · Cited by 591
Becht, E., de Reyniès, A., Giraldo, N. A., Pilati, C., Buttard, B., Lacroix, L., Selves, J., Sautès-Fridman, C., Laurent-Puig, P., & Fridman, W. H. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2879 · Cited by 590
Structure-guided blockade of CSF1R kinase in tenosynovial giant-cell tumor
Tap, W. D., Wainberg, Z. A., Anthony, S. P., Ibrahim, P. N., Zhang, C., Healey, J. H., Chmielowski, B., Staddon, A. P., Cohn, A. L., Shapiro, G. I., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411366 · Cited by 582 · cited 2×
“In this study, we used PLX3397 (pexidartinib), a clinically tested inhibitor of CSF1 receptor, Flt3, and c-kit, but also PLX5622, a more specific CSF-1R inhibitor, to deplete TAMs and assess its consequence on resident CD8 T cells (15, 16).”
MethodMikucki, M. E., Fisher, D. T., Matsuzaki, J., Skitzki, J. J., Gaulin, N. B., Muhitch, J. B., Ku, A. W., Frelinger, J. G., Odunsi, K., Gajewski, T. F., et al. (2015) · Nature Communications · doi:10.1038/ncomms8458 · Cited by 512 · cited 1×
“Evidence suggests a requirement for the CXCR3CXCL9/CXCL10 axis for CD8 T cell trafficking to tumors (28).”
BackgroundDagher, N. N., Najafi, A. R., Kayala, K. M. N., Elmore, M. R. P., White, T. E., Medeiros, R., West, B. L., & Green, K. N. (2015) · Journal of Neuroinflammation · doi:10.1186/s12974-015-0366-9 · Cited by 505
Melero, I., Rouzaut, A., Motz, G. T., & Coukos, G. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0985 · Cited by 435
T cell migration, search strategies and mechanisms
Krummel, M. F., Bartumeus, F., & Gérard, A. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2015.16 · Cited by 423
Lesokhin, A. M., Hohl, T. M., Kitano, S., Cortez, C., Hirschhorn-Cymerman, D., Avogadri, F., Rizzuto, G. A., Lazarus, J. J., Pamer, E. G., Houghton, A. N., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1792 · Cited by 378
In vivo imaging of cytotoxic T cell infiltration and elimination of a solid tumor
Boissonnas, A., Fetler, L., Zeelenberg, I. S., Hugues, S., & Amigorena, S. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20061890 · Cited by 377
Strachan, D. C., Ruffell, B., Oei, Y., Bissell, M. J., Coussens, L. M., Pryer, N., & Daniel, D. (2013) · OncoImmunology · doi:10.4161/onci.26968 · Cited by 376
Tumor macrophages are pivotal constructors of tumor collagenous matrix
Afik, R., Zigmond, E., Vugman, M., Klepfish, M., Shimshoni, E., Pasmanik-Chor, M., Shenoy, A., Bassat, E., Halpern, Z., Geiger, T., et al. (2016) · Journal of Experimental Medicine · doi:10.1084/jem.20151193 · Cited by 375
Effector T-cell trafficking between the leptomeninges and the cerebrospinal fluid
Schläger, C., Körner, H., Krueger, M., Vidoli, S., Haberl, M., Mielke, D., Brylla, E., Issekutz, T., Cabañas, C., Nelson, P. J., et al. (2016) · Nature · doi:10.1038/nature16939 · Cited by 372
Macrophage and T Cell Dynamics during the Development and Disintegration of Mycobacterial Granulomas
Egen, J. G., Rothfuchs, A. G., Feng, C. G., Winter, N., Sher, A., & Germain, R. N. (2008) · Immunity · doi:10.1016/j.immuni.2007.12.010 · Cited by 356
Engelhardt, J. J., Boldajipour, B., Beemiller, P., Pandurangi, P., Sorensen, C., Werb, Z., Egeblad, M., & Krummel, M. F. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.01.008 · Cited by 330
Inhibition of CSF-1 Receptor Improves the Antitumor Efficacy of Adoptive Cell Transfer Immunotherapy
Mok, S., Koya, R. C., Tsui, C., Xu, J., Robert, L., Wu, L., Graeber, T. G., West, B. L., Bollag, G., & Ribas, A. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1816 · Cited by 309
PD-1 promotes immune exhaustion by inducing antiviral T cell motility paralysis
Zinselmeyer, B. H., Heydari, S., Sacristán, C., Nayak, D., Cammer, M., Herz, J., Cheng, X., Davis, S. J., Dustin, M. L., & McGavern, D. B. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20121416 · Cited by 258
Honda, T., Egen, J. G., Lämmermann, T., Kastenmüller, W., Torabi-Parizi, P., & Germain, R. N. (2014) · Immunity · doi:10.1016/j.immuni.2013.11.017 · Cited by 237
Random migration precedes stable target cell interactions of tumor-infiltrating T cells
Mrass, P., Takano, H., Ng, L. G., Daxini, S., Lasaro, M. O., Iparraguirre, A., Cavanagh, L. L., von Andrian, U. H., Ertl, H. C. J., Haydon, P. G., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20060710 · Cited by 229
Leukocyte migration in the interstitial space of non-lymphoid organs
Weninger, W., Biro, M., & Jain, R. (2014) · Nature Reviews Immunology · doi:10.1038/nri3641 · Cited by 213
Borowsky, A. D., Namba, R., Young, L. J. T., Hunter, K. W., Hodgson, J. G., Tepper, C. G., McGoldrick, E. T., Muller, W. J., Cardiff, R. D., & Gregg, J. P. (2005) · Clinical & Experimental Metastasis · doi:10.1007/s10585-005-2908-5 · Cited by 194
Suppressing T cell motility induced by anti–CTLA-4 monotherapy improves antitumor effects
Ruocco, M. G., Pilones, K. A., Kawashima, N., Cammer, M., Huang, J., Babb, J. S., Liu, M., Formenti, S. C., Dustin, M. L., & Demaria, S. (2012) · Journal of Clinical Investigation · doi:10.1172/jci61931 · Cited by 187
Gordon-Alonso, M., Hirsch, T., Wildmann, C., & van der Bruggen, P. (2017) · Nature Communications · doi:10.1038/s41467-017-00925-6 · Cited by 186
Deguine, J., Bréart, B., Lemaître, F., Santo, J. P. D., & Bousso, P. (2010) · Immunity · doi:10.1016/j.immuni.2010.09.016 · Cited by 168
Bougherara, H., Mansuet‐Lupo, A., Alifano, M., Ngô, C., Damotte, D., Frère‐Belda, M. L., Donnadieu, E., & Peranzoni, E. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00500 · Cited by 162
Self-citationFocusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb
Weigelin, B., Bolaños, E., Teijeira, Á., Martínez‐Forero, I., Labiano, S., Azpilikueta, A., Morales‐Kastresana, A., Quetglas, J. I., Wagena, E., Sánchez-Paulete, A. R., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1506357112 · Cited by 127
CD8+ Tumor-Infiltrating T Cells Are Trapped in the Tumor-Dendritic Cell Network
Boissonnas, A., Licata, F., Poupel, L., Jacquelin, S., Fetler, L., Krumeich, S., Théry, C., Amigorena, S., & Combadière, C. (2013) · Neoplasia · doi:10.1593/neo.121572 · Cited by 117
Positive and negative influence of the matrix architecture on antitumor immune surveillance
Peranzoni, E., Rivas-Caicedo, A., Bougherara, H., Salmon, H., & Donnadieu, E. (2013) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1339-8 · Cited by 117
Self-citationHarnessing the antitumor potential of macrophages for cancer immunotherapy
Long, K. B., & Beatty, G. L. (2013) · OncoImmunology · doi:10.4161/onci.26860 · Cited by 114
Michonneau, D., Sagoo, P., Bréart, B., Garcia, Z., Celli, S., & Bousso, P. (2016) · Immunity · doi:10.1016/j.immuni.2015.12.008 · Cited by 91
Reprogramming of macrophages — new opportunities for therapeutic targeting
Schultze, J. L. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2015.09.007 · Cited by 86
TCR-engineered T cells to treat tumors: Seeing but not touching?
Debets, R., Donnadieu, E., Chouaïb, S., & Coukos, G. (2016) · Seminars in Immunology · doi:10.1016/j.smim.2016.03.002 · Cited by 79
Self-citationThoreau, M., Penny, H. L., Tan, K. W., Régnier, F., Weiss, J. M., Lee, B. T. K., Johannes, L., Dransart, E., Bon, A. L., Abastado, J., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4940 · Cited by 74
Self-citationTumor stroma and chemokines control T-cell migration into melanoma following Temozolomide treatment
Tan, K. W., Evrard, M., Tham, M., Hong, M. L. W., Huang, C. W., Kato, M., Prévost‐Blondel, A., Donnadieu, E., Ng, L. G., & Abastado, J. (2015) · OncoImmunology · doi:10.4161/2162402x.2014.978709 · Cited by 45
Self-citationAudemard‐Verger, A., Rivière, M., Durand, A., Peranzoni, E., Guichard, V., Hamon, P., Bonilla, N., Guilbert, T., Boissonnas, A., Auffray, C., et al. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1700430 · Cited by 17
Self-citation
Cited by
Macrophages as regulators of tumour immunity and immunotherapy
DeNardo, D. G., & Ruffell, B. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-019-0127-6 · Cited by 2,528
Tumor microenvironment as a therapeutic target in cancer
Xiao, Y., & Yu, D. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107753 · Cited by 1,957
Macrophages and metabolism in the tumor microenvironment
Vitale, I., Manic, G., Coussens, L. M., Kroemer, G., & Galluzzi, L. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.06.001 · Cited by 1,837
Macrophages as tools and targets in cancer therapy
Mantovani, A., Allavena, P., Marchesi, F., & Garlanda, C. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00520-5 · Cited by 1,807
Landscape and Dynamics of Single Immune Cells in Hepatocellular Carcinoma
Zhang, Q., He, Y., Luo, N., Patel, S. J., Han, Y., Gao, R., Modak, M., Carotta, S., Haslinger, C., Kind, D., et al. (2019) · Cell · doi:10.1016/j.cell.2019.10.003 · Cited by 1,624
Metadata
- Authors
- Peranzoni, E., Lemoine, J., Vimeux, L., Feuillet, V., Barrin, S., Kantari-Mimoun, C., Bercovici, N., Guérin, M., Biton, J., Ouakrim, H., Régnier, F., Lupo, A., Alifano, M., Damotte, D., & Donnadieu, E.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2018-04-09
- Volume
- 115
- Issue
- 17
- Pages
- E4041-E4050
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2797866384
- Cited by
- 919
- References
- 54
- FWCI
- 27.72
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.